nach oben

CNS Drugs

Erschienen in:

01.09.2015 | Leading Article

Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics

verfasst von: Elizabeth Fox-Edmiston, Judy Van de Water

Erschienen in: CNS Drugs | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum disorder (ASD). Studies by our laboratory elucidated seven neurodevelopmental proteins recognized by maternal autoantibodies whose presence is associated with a diagnosis of maternal autoantibody-related (MAR) autism in the child. While the specific process of anti-brain autoantibody generation is unclear and the detailed pathogenic mechanisms are currently unknown, identification of the maternal autoantibody targets increases the therapeutic possibilities. The potential therapies discussed in this review provide a framework for possible future medical interventions.

American Psychiatric Association. DSM-5 autism spectrum disorder fact sheet. 2013. http://www.dsm5.org/Documents/Autism%20Spectrum%20Disorder%20Fact%20Sheet.pdf. Accessed 24 Aug 2015.

Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN. The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. Environ Health Perspect. 2006;114(7):1119–25.

Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011;68(11):1095–102. doi:10.1001/archgenpsychiatry.2011.76.PubMedCentralCrossRefPubMed

Braunschweig D, Van de Water J. Maternal autoantibodies in autism. Arch Neurol. 2012;69(6):693–9. doi:10.1001/archneurol.2011.2506.CrossRefPubMed

Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi:10.1155/2012/985646.PubMedCentralCrossRefPubMed

Braunschweig D, Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Croen LA, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology. 2008;29(2):226–31. doi:10.1016/j.neuro.2007.10.010.PubMedCentralPubMed

Braunschweig D, Duncanson P, Boyce R, Hansen R, Ashwood P, Pessah IN, et al. Behavioral correlates of maternal antibody status among children with autism. J Autism Dev Disord. 2012;42(7):1435–45. doi:10.1007/s10803-011-1378-7.CrossRefPubMed

Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I–related receptor FcRn. Annu Rev Immunol. 2000;18(1):739–66. doi:10.1146/annurev.immunol.18.1.739.CrossRefPubMed

Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol. 1994;1(6):667–9.PubMedCentralPubMed

10.

Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21(24):3365–9.CrossRefPubMed

11.

Goines P, Van de Water J. The immune system’s role in the biology of autism. Curr Opin Neurol. 2010;23(2):111–7. doi:10.1097/WCO.0b013e3283373514.PubMedCentralCrossRefPubMed

12.

Dalton P, Deacon R, Blamire A, Pike M, McKinlay I, Stein J, et al. Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol. 2003;53(4):533–7. doi:10.1002/ana.10557.CrossRefPubMed

13.

Singer HS, Morris CM, Williams PN, Yoon DY, Hong JJ, Zimmerman AW. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol. 2006;178(1–2):149–55. doi:10.1016/j.jneuroim.2006.05.025.CrossRefPubMed

14.

Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA, et al. Maternal antibrain antibodies in autism. Brain Behav Immun. 2007;21(3):351–7. doi:10.1016/j.bbi.2006.08.005.CrossRefPubMed

15.

Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol. 2008;194(1–2):165–72. doi:10.1016/j.jneuroim.2007.11.004.CrossRefPubMed

16.

Croen LA, Braunschweig D, Haapanen L, Yoshida CK, Fireman B, Grether JK, et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol Psychiatry. 2008;64(7):583–8. doi:10.1016/j.biopsych.2008.05.006.PubMedCentralCrossRefPubMed

17.

Braunschweig D, Krakowiak P, Duncanson P, Boyce R, Hansen RL, Ashwood P, et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl Psychiatry. 2013;3:e277. doi:10.1038/tp.2013.50.PubMedCentralCrossRefPubMed

18.

Brimberg L, Sadiq A, Gregersen PK, Diamond B. Brain-reactive IgG correlates with autoimmunity in mothers of a child with an autism spectrum disorder. Mol Psychiatry. 2013;18(11):1171–7.CrossRefPubMed

19.

Nandakumar KS, Holmdahl R. Therapeutic cleavage of IgG: new avenues for treating inflammation. Trends Immunol. 2008;29(4):173–8. doi:10.1016/j.it.2008.01.007.CrossRefPubMed

20.

Christen U, von Herrath MG. Initiation of autoimmunity. Curr Opin Immunol. 2004;16(6):759–67. doi:10.1016/j.coi.2004.09.002.CrossRefPubMed

21.

Atladóttir HÓ, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics. 2009;124(2):687–94. doi:10.1542/peds.2008-2445.CrossRefPubMed

22.

Diamond B, Honig G, Mader S, Brimberg L, Volpe BT. Brain-reactive antibodies and disease. Annu Rev Immunol. 2013;31(1):345–85. doi:10.1146/annurev-immunol-020711-075041.PubMedCentralCrossRefPubMed

23.

Ingudomnukul E, Baron-Cohen S, Wheelwright S, Knickmeyer R. Elevated rates of testosterone-related disorders in women with autism spectrum conditions. Horm Behav. 2007;51(5):597–604. doi:10.1016/j.yhbeh.2007.02.001.CrossRefPubMed

24.

Fairthorne J, Hammond G, Bourke J, Jacoby P, Leonard H. Early mortality and primary causes of death in mothers of children with intellectual disability or autism spectrum disorder: a retrospective cohort study. PLoS One. 2014;9(12):e113430. doi:10.1371/journal.pone.0113430.PubMedCentralCrossRefPubMed

25.

Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, et al. Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse. Eur J Surg Oncol. 2014;40(3):289–96. doi:10.1016/j.ejso.2013.09.008.CrossRefPubMed

26.

Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT. Losing your nerves? Maybe it’s the antibodies. Nat Rev Immunol. 2009;9(6):449–56. doi:10.1038/nri2529.PubMedCentralCrossRefPubMed

27.

Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci. 2005;1051(1):635–46. doi:10.1196/annals.1361.108.CrossRefPubMed

28.

Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008;22(6):806–16. doi:10.1016/j.bbi.2007.12.007.

29.

Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: a pregnant dam mouse model. J Neuroimmunol. 2009;211(1–2):39–48. doi:10.1016/j.jneuroim.2009.03.011.CrossRefPubMed

30.

Braunschweig D, Golub MS, Koenig CM, Qi L, Pessah IN, Van de Water J, et al. Maternal autism-associated IgG antibodies delay development and produce anxiety in a mouse gestational transfer model. J Neuroimmunol. 2012;252(1):56–65.

31.

Bauman MD, Iosif AM, Ashwood P, Braunschweig D, Lee A, Schumann CM, et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl Psychiatry. 2013;3:e278. doi:10.1038/tp.2013.47.PubMedCentralCrossRefPubMed

32.

Martínez-Cerdeño V, Camacho J, Fox E, Miller E, Ariza J, Kienzle D, et al. Prenatal exposure to autism-specific maternal autoantibodies alters proliferation of cortical neural precursor cells, enlarges brain, and increases neuronal size in adult animals. Cerebral Cortex. 2014. doi:10.1093/cercor/bhu291 (Epub 2014 Dec 22).PubMed

33.

Nordahl CW, Braunschweig D, Iosif A-M, Lee A, Rogers S, Ashwood P, et al. Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder. Brain Behav Immun. 2013;30:61–5. doi:10.1016/j.bbi.2013.01.084.PubMedCentralCrossRefPubMed

34.

Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, et al. Cognition and immunity; antibody impairs memory. Immunity. 2004;21(2):179–88. doi:10.1016/j.immuni.2004.07.011.CrossRefPubMed

35.

Rönspeck W, Brinckmann R, Egner R, Gebauer F, Winkler D, Jekow P, et al. Peptide based adsorbers for therapeutic immunoadsorption. Therapeutic apheresis and dialysis. 2003;7(1):91–7. doi:10.1046/j.1526-0968.2003.00017.x.

36.

Schröder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother. 2009;9(9):1331–9. doi:10.1586/ern.09.81.CrossRefPubMed

37.

Claude RJ, Sylvie C, AC HR, Djillali A. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(7):CD001798. doi:10.1002/14651858.CD001798.pub2.

38.

Goding JW. Use of staphylococcal protein A as an immunological reagent. J Immunol Methods. 1978;20:241–53. doi:10.1016/0022-1759(78)90259-4.CrossRefPubMed

39.

Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol. 2005;23(1):367–86. doi:10.1146/annurev.immunol.23.021704.115723.CrossRefPubMed

40.

Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2009;7(9):715–25. doi:10.1038/nri2155.CrossRef

41.

Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283–8.CrossRefPubMed

42.

Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176–89.CrossRefPubMed

43.

Bloom O, Cheng KF, He M, Papatheodorou A, Volpe BT, Diamond B, et al. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc Natl Acad Sci. 2011;108(25):10255–9. doi:10.1073/pnas.1103555108.PubMedCentralCrossRefPubMed

44.

Diamond B, Volpe BT. A model for lupus brain disease. Immunol Rev. 2012;248(1):56–67. doi:10.1111/j.1600-065X.2012.01137.x.PubMedCentralCrossRefPubMed

45.

Murphy K. Janeway’s immunobiology. 8th ed. New York: Garland Science; 2011.

46.

Schifferli JA, Ng YC, Peters DK. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med. 1986;315(8):488–95. doi:10.1056/NEJM198608213150805.CrossRefPubMed

47.

Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27(40):10695–702.PubMedCentralCrossRefPubMed

48.

Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748–55.CrossRefPubMed

49.

Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64(2):493–503. doi:10.1002/art.33333.PubMedCentralCrossRefPubMed

50.

Gomez AM, Willcox N, Molenaar PC, Buurman W, Martinez-Martinez P, De Baets MH, et al. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? Ann N Y Acad Sci. 2012;1274(1):48–59. doi:10.1111/j.1749-6632.2012.06824.x.CrossRefPubMed

Titel: Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics
verfasst von: Elizabeth Fox-Edmiston
Judy Van de Water
Publikationsdatum: 01.09.2015
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 9/2015
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-015-0279-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2015

Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder

Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis

N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study

A Common Reference-Based Indirect Comparison Meta-Analysis of Buccal versus Intranasal Midazolam for Early Status Epilepticus

Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie